Looking for predictive markers in breast cancer

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages e1-

  Bonotto, Marta ^a,b   Fontanella, Caterina ^a,b   Puglisi, Fabio ^a,b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; TAXOID;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; ENZYME INDUCTION; HUMAN; LETTER; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; FEMALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; TAXOIDS;

EID: 84926131905     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71107-6     Document Type: Letter

References (5)

1. Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15:1351-1360.
2. Bonotto M, Bozza C, Di Loreto C, et al. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?. Clin Breast Cancer 2013, 13:167-172.
3. Toi M, Bando H, Horiguchi S, et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 2004, 90:2338-2343.
4. Puglisi F, Andreetta C, Valent F, et al. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs 2007, 18:883-888.
5. Andreetta C, Puppin C, Minisini A, et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 2009, 20:265-271.